AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
ANAB filed a patent for "btla agonist for modulation of dendritic cells" on Thu, May 25, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
